Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis

BMC Gastroenterology

Research

Noriyo Urata¹  Tomohiro Tanikawa¹  Ryo Katsumata¹  Jun Nakamura¹  Mayuko Kawada¹  Katsunori Ishii¹  Hirofumi Kawamoto¹  Ken Haruma¹  Ken Nishino¹  Mitsuhiko Suehiro¹  Miwa Kawanaka¹ 

[1] Department of General Internal Medicine, General Medical Center, Kawasaki Medical School, 2-6-1, Nakasange, Kita-ku, 700-8505, Okayama City, Okayama, Japan;

关键词: Nonalcoholic fatty liver disease;    Soluble CD163;    Hepatocellular carcinoma;    Cirrhosis;    Prognosis;   

DOI  :  10.1186/s12876-023-02786-4

 received in 2022-07-27, accepted in 2023-04-25,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundNonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The serum level of soluble CD163 (sCD163), a macrophage activation marker, is associated with liver tissue changes; however, its prognostic value is unknown. Here, we determined the utility of sCD163 as a marker for hepatocellular carcinoma (HCC) and prognostic marker for NAFLD.MethodsThis retrospective study obtained data regarding serum sCD163 levels, liver histology, and background factors associated with NAFLD in 287 patients (men/women, 140/147; average age, 53 ± 14 years) with NAFLD who underwent liver biopsy. Repeated liver biopsies of 287 patients with NAFLD (5.0 ± 2.7 years) were compared regarding serum sCD163 levels and liver tissue changes (stage, grade, steatosis, and NAFLD activity score).ResultsSerum sCD163 levels increased with the progression of liver fibrosis and inflammation (both P < 0.05) and were particularly helpful in distinguishing cases of Grade 4 fibrosis (P < 0.001). Levels of sCD163 significantly decreased in patients with NAFLD exhibiting alleviated fibrosis and inflammation (P < 0.05). We could also predict the development of HCC and associated mortality based on serum sCD163 levels at the time of NAFLD diagnosis. Serum sCD163 levels were higher in patients with HCC than in patients without HCC (1074 ± 379 ng/ml vs. 669 ± 261 ng/ml; P < 0.0001), and the same trend was observed for mortality.ConclusionsThe serum sCD163 level reflects the progression of fibrosis and inflammation in liver tissues, showing much promise as a noninvasive biomarker for nonalcoholic steatohepatitis and NAFLD as well as a possible predictor of HCC development and patient prognosis.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 22

Fig. 1